MedImmune HCC D4190C00022 for Liver Cancer - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn whether the study drugs Durvalumab, Tremelimumab, and bevacizumab are safe for patients, and whether the study drug regimen can reduce or slow the growth of your cancer.
Additionally, we want to learn what effects, good or bad, the study drugs may have on your body.
Who Can Participate in the Study?
- Have never had treatment with drugs similar to durvalumab, tremelimumab, or bevacizumab
- Have a body weight of at least 66 pounds
- Have hepatocellular carcinoma
What is Involved?
If you choose to join this study, you will receive a combination of the study drugs durvalumab and bevacizumab until your cancer gets worse or the study doctor decides to take you off the study.